Monopar Therapeutics Says Nasdaq Has Granted Co 180-Day Extension To Aug. 26 To Regain Compliance
Portfolio Pulse from Benzinga Newsdesk
Monopar Therapeutics has been granted a 180-day extension by Nasdaq until August 26 to regain compliance, according to an SEC filing.
February 28, 2024 | 7:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Monopar Therapeutics has received a 180-day extension from Nasdaq to regain compliance, as per an SEC filing.
The extension granted by Nasdaq is a positive development for Monopar Therapeutics, as it provides additional time for the company to meet Nasdaq's compliance requirements. This news is likely to be viewed positively by investors, as it reduces the immediate risk of delisting, potentially leading to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100